B

BioVie
D

BIVI

2.82000
USD
-0.18
(-6.00%)
Market Open
Volume
31,346
EPS
-1
Div Yield
-
P/E
-1
Market Cap
50,106,251
News

Title: BioVie Inc

Sector: Healthcare
Industry: Biotechnology
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.